Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14036911 | 1.00 | SLC7A5 (0.34) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| Hydrochloric Acid SCHEMBL4447018 | 0.98 | SLC7A5 (0.33) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| SCHEMBL722370 | 0.81 | SLC7A5 (0.50) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| SCHEMBL10436302 | 0.81 | SLC7A5 (0.50) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| SCHEMBL15368912 | 0.81 | TSHR (0.35) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| SCHEMBL20932872 | 0.81 | SLC7A5 (0.50) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| Hydrochloric Acid SCHEMBL23111921 | 0.79 | SLC7A5 (0.48) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| SCHEMBL25867906 | 0.79 | GABRP (0.33) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| SCHEMBL26315380 | 0.78 | TSHR (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5195709 | 0.77 | SMN1; SMN2 (0.37) | SLC7A5SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-22 | — | — | US | disclosed |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-22 | — | — | US | disclosed |
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | US | disclosed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8288391-B2 | Epithelial Sodium Channel and Acid Sensitive Ion Channel modulators; blocking or enhancing salt and sour tastes; additives in chocolate, ice cream, beverages, candies, or pet foods; side effect reduction | PARION SCIENCES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8124607-B2 | Poly aromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20080293740-A1 | METHOD OF TREATING ACID-SENSING ION CHANNEL MEDIATED PAIN, COUGH SUPPRESSION, AND CENTRAL NERVOUS SYSTEM DISORDERS | PARION SCIENCES, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20080249109-A1 | PYRAZINOYLGUANIDINE COMPOUNDS FOR USE AS TASTE MODULATORS | PARION SCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | BHMT2, BHMT, PTMS | SLC7A5 159/4885NOS3 647/4885NOS1 889/4885 |
| US-20080249109-A1 | PYRAZINOYLGUANIDINE COMPOUNDS FOR USE AS TASTE MODULATORS | TAS2R5, TAS2R9, TAS2R19 | SLC7A5 552/4885NOS3 2481/4885NOS1 2431/4885 |
| US-20080293740-A1 | METHOD OF TREATING ACID-SENSING ION CHANNEL MEDIATED PAIN, COUGH SUPPRESSION, AND CENTRAL NERVOUS SYSTEM DISORDERS | ASIC1, ASIC3, TRPV1 | SLC7A5 1683/4885NOS3 3700/4885NOS1 3842/4885 |
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | SLC7A5 2414/4885NOS3 508/4885NOS1 693/4885 |
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, KCNH1 | SLC7A5 1838/4885NOS3 2574/4885NOS1 2493/4885 |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | SLC7A5 1163/4885NOS3 2243/4885NOS1 2588/4885 |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | SLC7A5 1163/4885NOS3 2243/4885NOS1 2588/4885 |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | BHMT2, BHMT, PTMS | SLC7A5 159/4885NOS3 647/4885NOS1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.